Are pharma companies still fearful of the Inflation Reduction Act? Will Lykos’ FDA rejection and recent publication retractions pull down the entire psychedelics industry? And what would you name a commercial psychotherapy treatment?
We discuss all that and more on this week’s episode of “The Readout LOUD.”
STAT’s chief Washington correspondent Rachel Cohrs Zhang joins us to discuss the discounts and how this first round of negotiations between pharmaceutical companies and Medicare officials played out. After that, we chat with our colleague Meghana Keshavan about the latest news in the psychedelics world, including the retraction of three research papers.
For more on the negotiated drug prices, go here; For what this means for Vice President Kamala Harris’ presidential campaign, go here; For more on the FDA’s rejection of Lykos Therapeutics’ MDMA therapy, go here; For context on the adverse effects seen in the study, go here; And for details about the retractions made by the journal Psychopharmacology, go here.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
